Volume 4.35 | Sep 13

Prostate Cell News 4.35 September 13, 2013
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
 
TOP STORY
Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
Researchers demonstrated that the androgen receptor regulates a transcriptional program of DNA repair genes that promotes prostate cancer radioresistance, providing a potential mechanism by which androgen deprivation therapy synergizes with ionizing radiation. [Cancer Discov] Abstract | Full Article
[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Inhibition of Androgen Receptor and β-Catenin Activity in Prostate Cancer
Scientists provide proof-of-concept that a small-molecule inhibitor of nuclear β-catenin activity can inhibit both the androgen receptor and β-catenin-signaling pathways that are often misregulated in prostate cancer. [Proc Natl Acad Sci USA] Abstract

TBK1 Regulates Prostate Cancer Dormancy through mTOR Inhibition
Researchers investigated the effects of TANK binding kinase 1 (TBK1) on prostate cancer (PCa) dormancy in the bone marrow niche. They found that binding with niche osteoblasts induces the expression of TBK1 in PCa cells PC3 and C4-2B. [Neoplasia] Full Article

Selectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase Inhibitors
Investigators present the first example of histone deacetylase inhibitor compounds targeted to prostate tumors by equipping them with the additional ability to bind the androgen receptor with non-steroidal antiandrogen moieties. [ACS Chem Biol] Abstract

The HDAC Inhibitor LBH589 Induces ERK-Dependent Prometaphase Arrest in Prostate Cancer via HDAC6 Inactivation and Down-Regulation
Researchers determined if a potent histone deacetylase inhibitor (HDACI), LBH589, had differential therapeutic responsiveness towards LNCaP and PC-3 prostate cancer cells. The former showed prometaphase arrest with subsequent apoptosis upon LBH589 treatment, while the latter was less sensitive and had late G2 arrest. [PLoS One] Full Article

Nanoparticulate Paclitaxel Demonstrates Antitumor Activity in PC3 and Ace-1 Aggressive Prostate Cancer Cell Lines
Nanoparticulate paclitaxel was as effective as standard paclitaxel in decreasing cell viability, decreasing colony forming ability, and inducing apoptosis in human and canine prostate cancer cells in a dose-dependent manner. [Invest New Drugs] Abstract

Functional and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide and Docetaxel Regimen in Castration-Resistant Prostate Cancer
Scientists investigated the association of docetaxel and metronomic cyclophosphamide (CYC) in castration-resistant prostate cancer. Metronomic CYC is an effective adjuvant in blocking tumor growth in vivo, with comparable efficacy and less toxic effects compared with docetaxel treatment. [Future Oncol] Abstract

Flavonoids from Orostachys japonicus A. Berger Inhibit the Invasion of LnCaP Prostate Carcinoma Cells by Inactivating Akt and Modulating Tight Junctions
Researchers investigated the effects of flavonoids extracted from Orostachys japonicus A. Berger (FEOJ) on tight junctions and the expression of claudins as well as cancer invasion within LnCaP human prostate cancer. FEOJ suppressed cancer cell motility and invasiveness at the concentrations where FEOJ did not show anti-proliferative activity. [Int J Mol Sci] Abstract | Full Article

CLINICAL RESEARCH

Hypofractionated Intensity-Modulated Arc Therapy for Lymph Node Metastasized Prostate Cancer: Early Late Toxicity and 3-Year Clinical Outcome
The authors evaluated clinical outcome, gastro-intestinal and genito-urinary toxicity after intensity modulated arc radiotherapy and androgen deprivation for N1 prostate cancer. [Radiother Oncol] Abstract

G84E Mutation in HOXB13 Is Firmly Associated with Prostate Cancer Risk: A Meta-Analysis
In an attempt to confirm and expand the findings that the prostate cancer (PCa) risk increased in men carrying G84E, researchers performed a meta-analysis to clarify the association between the germline G84E mutation and PCa risk. They also aimed to verify the increased PCa risk with respect to diagnostic age, family history, and disease aggressiveness. [Tumor Biol] Abstract

Derivation of Metabolically Active Hepatocytes from Pluripotent Stem Cells - View On-Demand Webinar Now.
 
REVIEWS
Intraductal Carcinoma of the Prostate: The Whole Story
The authors review the historical aspect, diagnostic criteria, molecular genetics, and clinical significance of intraductal carcinoma of the prostate. [Pathology] Abstract

Visit our REVIEWS page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
Weill Cornell Medical College Receives $100 Million Gift from Joan and Sanford I. Weill and the Weill Family Foundation to Launch New Capital Campaign
Weill Cornell Medical College announced that it has received a $100 million gift to launch the Medical College’s $300 million Driving Discoveries, Changing Lives campaign dedicated to using the most advanced scientific approaches to rapidly translate research breakthroughs into innovative treatments and therapies for patients. [Weill Cornell Medical College] Press Release

New Hub Forms Part of ‘Industrial Revolution’ in Regenerative Medicine
Scientists at the Universities of Sheffield, Loughborough and Cambridge are set to lead a new £4.5 million ‘Hub’ aimed at translating lab discoveries into regenerative treatment to help sufferers of Parkinson’s disease and deafness. The Hub forms part of a £25 million investment from three UK Research Councils in research and equipment to support the development of regenerative medicine therapies for a range of applications, including Parkinson’s disease, cardiovascular disease, wound and musculoskeletal repair, eye disorders and deafness. [The University of Sheffield] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 1st Annual Conference of the German Stem Cell Network (GSCN)
November 11-13, 2013
Berlin, Germany

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Research Associate – Prostate Cancer (University of Virginia)

Postdoctoral Position – Prostate Molecular Biology and Cancer Biology (University of California San Francisco)

Postdoctoral Position – Prostate Cancer Biology (University Of Rochester School Of Medicine)

Postdoctoral Position – Cancer Genomics and Epigenomics (Ontario Cancer Institute / Princess Margaret Hospital)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Prostate Cancer Research (Mount Sinai School of Medicine)

Research Associate II – Anti-Cancer Agents for the Treatment of Prostate Cancer (Johnson & Johnson)

Postdoctoral Position – Prostate Cancer (Tulane University)

Faculty Position – Detection and Diagnosis of Solid Tumors (Stanford University)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Learn more about Prostate Cell News: Archives | Events | Contact Us